Study of C – Reactive Protein (hs-CRP) In Patients Of Acute Myocardial Infarction
Abstract
AIMS AND OBJECTIVE: To evaluate the level of hs-CRP in patients of acute myocardial infarction (AMI) and to correlate it with various complications of AMI and in-hospital outcome.
MATERIAL AND METHODS: A total of 90 subjects including 60 patients of AMI and 30 age and sex matched controls were included for study. The diagnosis of AMI was made on the basis of
WHO criteria. The blood sample was drawn for measurement of hs-CRP, Troponin T/I and Lipid profile within six hours of admission.
STUDY DESIGN: Prospective open labelled cohort study.
OBSERVATION AND RESULTS: The mean hs-CRP in controls and cases was 1.7±0.23 mg/l and 3.32 ±0.69 mg/l respectively. The mean hs-CRP in patients who expired was 4.61±1.20 mg/l,
whereas in those who survived was 2.81 ±1.42 mg/l (p < 0.001). The mean value of Troponin I in patients who expired was 5.47 ±1.7 ng/ml whereas in those who survived, was 3.03 ±1.55 ng/ml
(p < 0.001). The mean hs-CRP among cases with various complications of AMI (atrioventricular blocks ventricular tachycardia, and hypotension) was in high risk group (> 3 mg/l).
CONCLUSION: The level of hs-CRP in subjects presenting with AMI were elevated indicating the vulnerability of the atheromatous plaque. The adverse hospital outcome was correlated with
the hs-CRP levels in higher risk group (> 3 mg/l). Finally a correlation was observed between levels of hs-CRP and complications of AMI though statistically insignificant. Hence hs–CRP
may be used as a marker of short term prognosis in patients of AMI along with conventional markers like Troponin T / I.
References
2. Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C- reactive protein during follow up of patients with acute coronary syndromes in the Aggrastat - to - Zocor Trial. Circulation.
2006;114:281.
3. Morrow D, Rifai N, Antman E, et al. C-reactive protein is a potent predictor of mortality independently and in combination with Troponin T in acute coronary syndrome: a TIMI 11 A substudy. J
Am Coll Cardiol. 1998;31: 1460 – 65.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801- 809.
5. Ferreiros ER, Boissonet CP, Pizarro et al. Independent prognostic value of elevated C – reactive protein in unstable angina. Circulation. 1999;100: 1958-1963.
6. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C- reactive protein and Troponon T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. J AM Coll Cardiol. 2000; 35:1535-1542.
7. Cesari M, Penninx BWJH, Newman AB, et al. Inflammatory markers and cardiovascular disease (the Health, Aging and Body composition [Health ABC] study) Am J Cardiol. 2003;92:522-528.
8. Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br Med J. 2000;321:199-204.
9. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in prediction of coronary Instability in Coronary Artery Disease. N Engl J Med. 2004;350:1387-97.
10. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort study, 1984 to 1992. Circulation. 1999;99:237-242.
11. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISK Study Group. Fragmin during
Instability in Coronary Artery Disease. Circulation. 1997;96:4204-10.
12. Biasucci LM, Liuzzo G, RL, et al. Elevated levels of Creactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999;99:855-860.
13. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839-844.
14. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
15. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. JAMA. 2007;297:611-619.
16. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J. 2000;140: 324-328.
17. Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in U. S. adults. JAMA. 2005;293:1868.
18. Rastogi T, Vaz M, Spiegelman D, Reddy KS, Bharathi AV, Stamper MJ, et al. Physical activity and risk of coronary heart disease in India. Int J Epidemiol. 2004;33:759-67.
